Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Personalized Immune Mouse Model Offers New Way to Research Autoimmune Diseases

By BiotechDaily International staff writers
Posted on 28 Mar 2012
A newly created mouse model may allow development of customized immunotherapies against cancer and infection.

Columbia University Medical Center (CUMC; New York, NY, USA) scientists have developed a way to recreate an individual’s immune system in a mouse. The “personalized immune mouse” provides researchers with an extraordinary tool for individualized analysis of abnormalities that contribute to type 1 diabetes and other autoimmune disorders, beginning at the onset of disease. The study’s findings were published March 14, 2012, in the online edition of the journal Science Translational Medicine.

The mouse model could also have clinical applications, such as predicting how a specific patient might respond to existing drugs or immunotherapies, reports senior author Megan Sykes, a professor of medicine and professor of microbiology and immunology and Surgical Sciences (in surgery) at CUMC. Dr. Sykes is also director for the Columbia Center for Translational Immunology.

Moreover, the model might be useful for developing individualized immunotherapies for combating infection or cancer or for lessening a patient's rejection of transplanted tissue.

Researchers have been searching for new ways to tease apart the various factors that contribute to autoimmune disease. “While large-scale studies of human populations have provided important clues to the genetic basis of immune diseases, they have offered little information about the specific role the genes play,” said Dr. Sykes. “It’s difficult to isolate these mechanisms when looking at groups of patients who have had disease for different lengths of time or have been receiving different treatments. And the fact that they already have the disease makes it difficult to distinguish what underlies and propagates the autoimmune process.”

Several research groups have attempted to create a personalized immune mouse. However, each model has had significant limitations, such as an inability to generate the full complement of immune cells and incompatibilities between tissues used to recreate the human immune system, leading to graft-versus-host disease.

Dr. Sykes’ model, in contrast, is able to recreate a healthy and diverse human immune system, including T cells, B cells, and myeloid cells (which generate a variety of immune cells), free of immune incompatibilities.

The model was created by transplanting human bone marrow stem cells (also known as CD34+ cells), along with a small amount (about 1 cubic mm) of human leukocyte antigen- (HLA)-matched immature thymus tissue, into an immunodeficient mouse. (The HLA system mediates interactions among various immune cells.) The thymus tissue is implanted into the mouse’s kidney capsule, a thin membrane that envelops the kidney and serves as an incubator. Within six to eight weeks, the transplanted thymus tissue is seeded by circulating human CD34+ cells (which are infused into the bloodstream of the mouse), and begins generating human immune cells from the CD34+ cells.

A key to the model’s effectiveness was the investigators’ finding that freezing and thawing the transplanted thymus tissue, as well as administering antibodies against CD2 (a glycoprotein that mediates T cell development and activation), depletes mature T cells from the tissue graft. This prevents rejection of the human CD34+ cells and graft-versus-host disease, while maintaining function of the thymus tissue.

Dr. Sykes plans to use the personalized immune mouse to study type 1 diabetes. “We hope to find out what is fundamentally different about patients’ immune systems, compared with those of healthy individuals, before any disease develops,” she said.

The studies should also clarify more about the genetics of type 1 diabetes. “A number of HLA-associated genes have been linked to type 1 diabetes,” she explained. “About a third of the population has one of more of these genes. But a much smaller percentage of the population actually develops the disease. What this means is, the HLA genes are necessary, but not sufficient, to cause type 1 diabetes. Using the personalized immune mouse, we expect to learn more about the role that non-HLA genes play in the disease.”

Related Links:

Columbia University Medical Center




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.